. Author manuscript; available in PMC: 2022 Sep 6.

Published in final edited form as: Lancet Haematol. 2019 Mar 22;6(5):e266–e275. doi: 10.1016/S2352-3026(19)30023-7

Table 3.

Fitted Bayesian piecewise exponential survival time regression model for progression-free survival time (N=157, number of events=39)

	Posterior Quantities
Variable	Mean of β	SD of β	Posterior 95% Credible Interval		Pr(β > 0 \| Data)
Bu-Mel	−0.572	0.342	−1.258	0.077	0.045
> 65 years of age	−0.007	0.418	−0.826	0.795	0.513
High-Cytogenetic Risk	0.200	0.395	−0.555	0.983	0.697
R-ISS Stage III	0.235	0.389	−0.563	0.957	0.730
PR or better to induction therapy	−0.375	0.639	−1.552	0.893	0.256
2^nd Randomization Algorithm	−0.296	0.862	−2.055	1.289	0.397

R-ISS, revised international staging system; PR, partial response